CAJ | 학술논문

目的：检测ERCC1、Rad51和P53在晚期非小细胞肺癌中的表达，探讨其临床意义和与铂类药物化疗疗效的相关性。方法选取我院2012年6月～2013年6月诊断为晚期非小细胞肺癌的68例患者病理学标本，采用免疫荧光组织化学染色法检测晚期非小细胞肺癌患者标本和外周淋巴血细胞中ERCC1、Rad51和P53的表达，观察ERCC1、Rad51和P53在晚期非小细胞肺癌患者标本和外周淋巴血细胞中表达的相关性；给予患者2～4个疗程铂类为基础的标准化疗方案，评价ERCC1、Rad51和P53蛋白的表达与化疗疗效相关性。结果晚期非小细胞肺癌患者标本和外周淋巴血细胞中ERCC1、Rad51和P53阳性率（分别为42.6%、35.3%和45.6%）和阴性表达率（分别为33.8%、27.9%和38.2%）相同，呈显著正相关（均P＜0.05）；ERCC1、Rad51和P53蛋白表达在患者年龄、性别、TNM分期、病理类型间无统计学意义（P＜0.05）；ERCC1阳性表达患者铂类药物化疗后总有效率为41.2%，显著低于阴性患者化疗后总有效率73.9%（P＜0.05）；Rad51阳性表达患者化疗后总有效率33.3%显著低于阴性表达患者化疗后总有效率63.2%（P＜0.05）；P53阳性表达患者铂类药物化疗后总有效率为29.0%，显著低于阴性患者化疗后总有效率53.8%（P＜0.05）。结论检测晚期非小细胞肺癌患者外周淋巴血细胞中ERCC1、Rad51和P53表达可很好反映其在癌组织中的表达情况；ERCC1、Rad51和P53表达较低的患者铂类药物治疗有效率更好，ERCC1、Rad51和P53对化疗疗效的预测为负相关。
목적：검측ERCC1、Rad51화P53재만기비소세포폐암중적표체，탐토기림상의의화여박류약물화료료효적상관성。방법선취아원2012년6월～2013년6월진단위만기비소세포폐암적68례환자병이학표본，채용면역형광조직화학염색법검측만기비소세포폐암환자표본화외주림파혈세포중ERCC1、Rad51화P53적표체，관찰ERCC1、Rad51화P53재만기비소세포폐암환자표본화외주림파혈세포중표체적상관성；급여환자2～4개료정박류위기출적표준화료방안，평개ERCC1、Rad51화P53단백적표체여화료료효상관성。결과만기비소세포폐암환자표본화외주림파혈세포중ERCC1、Rad51화P53양성솔（분별위42.6%、35.3%화45.6%）화음성표체솔（분별위33.8%、27.9%화38.2%）상동，정현저정상관（균P＜0.05）；ERCC1、Rad51화P53단백표체재환자년령、성별、TNM분기、병리류형간무통계학의의（P＜0.05）；ERCC1양성표체환자박류약물화료후총유효솔위41.2%，현저저우음성환자화료후총유효솔73.9%（P＜0.05）；Rad51양성표체환자화료후총유효솔33.3%현저저우음성표체환자화료후총유효솔63.2%（P＜0.05）；P53양성표체환자박류약물화료후총유효솔위29.0%，현저저우음성환자화료후총유효솔53.8%（P＜0.05）。결론검측만기비소세포폐암환자외주림파혈세포중ERCC1、Rad51화P53표체가흔호반영기재암조직중적표체정황；ERCC1、Rad51화P53표체교저적환자박류약물치료유효솔경호，ERCC1、Rad51화P53대화료료효적예측위부상관。
Objective To test the expression of ERCC1,Rad51 and P53 protein in late non-small cell lung cancer and explore the clinical significance and the correlation with the effect of Platinum drugs chemotherapy. Methods The pathology specimens of 68 patients with late non-small cell lung cancer in our hospital from June 2012 to June 2013 were collected,used immunofluorescence histochemical staining method to test the expression of ERCC1,Rad51 and P53 in pathology specimens of late non-small cell lung cancer and peripheral lymphoid cells,the correlation between the expression in late non-small cell lung cancer and peripheral lymphoid cells was observed.Patients were treated by platinum standard chemotherapy regimens for 2-4weeks, the correlation between the expression of ERCC1,Rad51 and P53 with effect of Platinum drugs chemotherapy was evaluated. Results The positive rate (42.6%、35.3% and 45.6% respectively)and negative rate(33.8%、27.9% and 38.2% respectively)of ERCC1,Rad51 and P53 protein in late non-small cell lung cancer and peripheral lymphoid cells were same,there was a significant positive correlation(all P < 0.05).There was no significant of the expression of ERCC1,Rad51 and P53 in age/Sex,TNM stage and pathological types(P<0.05).The total effective rate of patients with ERCC1 positive expression after platinum drugs chemotherapy was 41.2% and significant lower than the effective rate(73.9%) of patients with ERCC1 negative expression(P<0.05);The total effective rate of patients with Rad51 positive expression after platinum drugs chemotherapy was 33.3% and significant lower than the effective rate(63.2%) of patients with Rad51 negative expression(P < 0.05);The total effective rate of patients with P53positive expression after platinum drugs chemotherapy was 29.0% and significant lower than the effective rate(58.3%) of patients with P53 negative expression(P < 0.05). Conclusion Test the expression of ERCC1,Rad51 and P53 protein in peripheral lymphoid cells of patients with late non-small cell lung cancer and explore can reflect the expression in the cancer tissue very well,the effect of Platinum drugs chemotherapy for patients with ERCC1 negative expression is more better.There has a negative correlation between the expression of ERCC1,Rad51 and P53 protein between the effect of Platinum drugs chemotherapy.